RxDoctor Payments Data

Jill Rau, MD

Neurology · Scottsdale, AZNPI 1316474216

Payments from drug & device makers

$178,200in general payments, 2019–2025

Across 194 payments — averaging $918.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Innovation$119K
  • AbbVie$52K
  • Lundbeck LLC$4K
  • Amgen$2K
  • Averitas Pharma Inc.$180
  • Siemens Medical Solutions USA, Inc.$160
  • plus $359 from 6 others

What the payments were for

  • Consulting fees$4,1837%
  • Speaking & faculty fees$52,27388%
  • Travel & lodging$2340%
  • Food & beverage$2,6324%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$178,200 in reported general payments places this provider in the 80th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$156,300
Medicare patients
103
Services billed
21,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant141$190,200
Emgality PenGalcanezumab-Gnlm110$98,746
QuliptaAtogepant84$96,063
Nurtec OdtRimegepant Sulfate62$80,886
Ajovy AutoinjectorFremanezumab-Vfrm68$61,841
Aimovig AutoinjectorErenumab-Aooe71$54,536
Sumatriptan Succinate102$9,945
Eletriptan HbrEletriptan Hydrobromide50$4,426
Candesartan Cilexetil60$3,909
Naratriptan Hcl94$3,060
Acetazolamide16$2,235
Zolmitriptan17$1,960
Pregabalin17$1,877
RizatriptanRizatriptan Benzoate128$1,829
Memantine Hcl35$1,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$52,275$286,262225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 neurology providers in Arizona.

Other neurology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →